• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

识别白细胞介素-1抑制治疗的候选患者:来自真实病例的经验教训。

Identifying Patient Candidates for IL-1 Inhibition: Lessons From Real-World Cases.

作者信息

Avram Annalina, Duarte Cátia, Santos Maria José, Papagoras Charalampos, Ritis Konstantinos, Scarpioni Roberto, Schmidt Wolfgang A, Skendros Panagiotis

机构信息

Medical Doctor; Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin - Buch, Berlin, Germany.

Rheumatologist, Rheumatology Department, Centro Hospitalar, Universitario de Coimbra, Coimbra, Portugal.

出版信息

Joint Bone Spine. 2015 Oct;82 Suppl 1:eS17-29. doi: 10.1016/S1297-319X(15)30004-X.

DOI:10.1016/S1297-319X(15)30004-X
PMID:26717798
Abstract

A subgroup of patients with gouty arthritis have a chronic recurring form that is particularly difficult to treat. Such patients experience repeated flares and often have abundant tophi. Many also have underlying comorbidities, such as renal impairment, cardiovascular disease, gastrointestinal disorders, obesity, and hypertension, which contraindicate the use of standard anti-inflammatory medications. Five patients with difficult to treat gouty arthritis who were either candidates and/or treated with anti-IL therapy are described.

摘要

痛风性关节炎患者的一个亚组患有慢性复发性形式,这种形式特别难以治疗。这类患者经历反复发作,且常常有大量痛风石。许多患者还伴有潜在的合并症,如肾功能损害、心血管疾病、胃肠道疾病、肥胖症和高血压,这些情况都禁忌使用标准的抗炎药物。本文描述了5例难治性痛风性关节炎患者,他们要么是抗白细胞介素治疗的候选者,要么接受了抗白细胞介素治疗。

相似文献

1
Identifying Patient Candidates for IL-1 Inhibition: Lessons From Real-World Cases.识别白细胞介素-1抑制治疗的候选患者:来自真实病例的经验教训。
Joint Bone Spine. 2015 Oct;82 Suppl 1:eS17-29. doi: 10.1016/S1297-319X(15)30004-X.
2
Canakinumab for the Patient With Difficult-to-Treat Gouty Arthritis: Review of the Clinical Evidence.卡那单抗治疗难治性痛风性关节炎患者:临床证据综述
Joint Bone Spine. 2015 Oct;82 Suppl 1:eS9-16. doi: 10.1016/S1297-319X(15)30003-8.
3
Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout.阿那白滞素治疗难治性慢性有结晶痛风
Int J Rheum Dis. 2011 Aug;14(3):e33-7. doi: 10.1111/j.1756-185X.2011.01629.x.
4
Interleukin-1 as a therapeutic target in gout.白细胞介素-1作为痛风的治疗靶点。
Curr Opin Rheumatol. 2015 Mar;27(2):156-63. doi: 10.1097/BOR.0000000000000143.
5
Prophylaxis of acute flares when initiating febuxostat for chronic gouty arthritis in a real-world clinical setting.在真实临床环境中,当开始使用非布司他治疗慢性痛风性关节炎时预防急性发作。
Mod Rheumatol. 2018 Mar;28(2):339-344. doi: 10.1080/14397595.2017.1318467. Epub 2017 May 9.
6
The Way Forward: Practical Clinical Considerations for the Use of Canakinumab in Patients With Difficult-to-Treat Gouty Arthritis.前进之路:在难治性痛风性关节炎患者中使用卡那单抗的实际临床考量
Joint Bone Spine. 2015 Oct;82 Suppl 1:eS30-2. doi: 10.1016/S1297-319X(15)30005-1.
7
Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions.卡那奴单抗治疗治疗选择有限的急性痛风性关节炎患者的疗效:两项随机、多中心、活性对照、双盲试验及其初步扩展的结果。
Ann Rheum Dis. 2012 Nov;71(11):1839-48. doi: 10.1136/annrheumdis-2011-200908. Epub 2012 May 14.
8
Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study.卡那奴单抗可降低别嘌醇治疗起始时急性痛风性关节炎发作的风险:一项双盲、随机研究的结果。
Ann Rheum Dis. 2011 Jul;70(7):1264-71. doi: 10.1136/ard.2010.144063. Epub 2011 May 3.
9
Current concepts in the treatment of gouty arthritis.痛风性关节炎治疗的当前观念。
Orthop Surg. 2013 Feb;5(1):6-12. doi: 10.1111/os.12024.
10
Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis.炎症的机制及急性痛风性关节炎炎症的临床处理。
J Clin Rheumatol. 2013 Jan;19(1):19-29. doi: 10.1097/RHU.0b013e31827d8790.

引用本文的文献

1
Effectiveness and safety of anakinra in gouty arthritis: A case series and review of the literature.阿那白滞素治疗痛风性关节炎的有效性和安全性:病例系列及文献综述
Front Med (Lausanne). 2023 Jan 12;9:1089993. doi: 10.3389/fmed.2022.1089993. eCollection 2022.
2
Off-label use of anti-IL-1 drugs in rheumatic diseases.抗白细胞介素-1 药物在风湿性疾病中的超适应证使用。
Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211006584. doi: 10.1177/20587384211006584.
3
[Rare manifestations of axial skeleton gouty arthropathy].[中轴骨骼痛风性关节病的罕见表现]
Internist (Berl). 2017 Feb;58(2):191-195. doi: 10.1007/s00108-016-0136-5.